Prognostic impact of concordant and discordant bone marrow involvement and cell-of-origin in Korean patients with diffuse large B-cell lymphoma treated with R-CHOP
- 21 May 2015
- journal article
- research article
- Published by BMJ in Journal of Clinical Pathology
- Vol. 68 (9), 733-738
- https://doi.org/10.1136/jclinpath-2014-202656
Abstract
Aims Previous studies have suggested many prognostic factors in diffuse large B-cell lymphoma (DLBCL), but the prognostic importance of cell-of-origin and discordant bone marrow involvement remains unclear. The aim of this study was to evaluate the prognostic impact of bone marrow involvement histological subtype, cell-of-origin subtype and international prognostic index (IPI) scores in patients with DLBCL. Methods Patients who were newly diagnosed with DLBCL and treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) were analysed. Clinical information was reviewed retrospectively. Patients were classified into negative, concordant and discordant bone marrow involvement by histological review. The cell-of-origin types were defined using immunohistochemical analysis. Results Both concordant and discordant bone marrow involvement had a negative prognostic impact on progression-free survival, independent of the standard and National Comprehensive Cancer Network (NCCN) IPI scores and cell-of-origin. Patients with non-germinal centre B-cell type showed significantly shorter progression-free survival than those with germinal centre B-cell type. However, non-germinal centre B-cell type did not have a prognostic impact on progression-free survival or overall survival after controlling for the standard and NCCN-IPI and bone marrow involvement. Conclusions Both concordant and discordant bone marrow involvement had an adverse prognostic impact on progression-free survival and overall survival; this was independent of the standard and NCCN-IPI and cell-of-origin (non-germinal centre B-cell type). The NCCN-IPI had more powerful prognostic value than the standard IPI (sIPI). The non-germinal centre B-cell type lost significant prognostic impact on progression-free survival after adjustment for standard and NCCN-IPI and bone marrow involvement.Keywords
This publication has 26 references indexed in Scilit:
- Evaluation of prognostic values of clinical and histopathologic characteristics in diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone therapyLeukemia & Lymphoma, 2011
- Diffuse large B‐cell lymphoma with concordant bone marrow involvement has peculiar genomic profile and poor clinical outcomeHematological Oncology, 2011
- Diffuse Large B-Cell Lymphoma in Chinese PatientsAmerican Journal of Clinical Pathology, 2010
- Prognostic impact of immunohistochemical biomarkers in diffuse large B‐cell lymphoma in the rituximab eraCancer Science, 2009
- Concordant but not discordant bone marrow involvement in diffuse large B-cell lymphoma predicts a poor clinical outcome independent of the International Prognostic IndexBlood, 2007
- Revised Response Criteria for Malignant LymphomaJournal of Clinical Oncology, 2007
- The prognostic impact of bone marrow involvement in patients with diffuse large cell lymphoma varies according to the degree of infiltration and presence of discordant marrow involvementEuropean Journal of Haematology, 2006
- Molecular Pathogenesis of Diffuse Large B-Cell LymphomaJournal of Clinical Oncology, 2005
- Diffuse large cell lymphomaCurrent Opinion in Oncology, 2001
- Distinct types of diffuse large B-cell lymphoma identified by gene expression profilingNature, 2000